Normal Volunteers
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Attovia TherapeuticsCA - San Carlos
2 programs2
ATTO-1310Phase 11 trial
ATTO-3712Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Attovia TherapeuticsATTO-3712
Attovia TherapeuticsATTO-1310
Bausch HealthMNTX tablet
Clinical Trials (3)
Total enrollment: 180 patients across 3 trials
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Start: Oct 2025Est. completion: Oct 202672 patients
Phase 1Recruiting
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
Start: Jan 2025Est. completion: May 2026108 patients
Phase 1Active Not Recruiting
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
Start: Feb 2004Est. completion: Mar 2004
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 180 patients
2 companies competing in this space